Program
gadopiclenol
Also written as “P03277”, “Gadopiclenol” and “Elucirem”.
Its studies are mostly in Brain Neoplasms · Central Nervous System Diseases · Renal Insufficiency, led by Guerbet.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Guerbet | 121 open or running | phase 3since Jun 11, 2019 | Dec 15, 2015 | Dec 31, 2027phase 3 · NCT07348640 |
Also a collaborator on its studies: bracco-imaging-s-p-a.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 15, 2015First study: phase 2 study in CNS LesionFirst studyNCT02633501 · 312 enrolled · United States, Belgium, Czechia and more
- Jul 16, 2018Phase 2 study in Healthy VolunteersNCT03603106 · 142 enrolled · Belgium
- Aug 31, 20182 phase 1 studiesNCT03657784, NCT03657264
- Nov 20, 2018Phase 2 study in Central Nervous System IndicationNCT03749252 · 80 enrolled · Bulgaria, Hungary, Poland and more
- Jun 11, 20192 phase 3 studiesNCT03986138, NCT03996447
- May 25, 2021Phase 1 study in PharmacokineticsNCT04906005 · 27 enrolled · Japan
- Oct 18, 2022Phase 2 study in Central Nervous System DiseasesNCT05590884 · 36 enrolled · United States, Hungary, Poland
- Jul 28, 2023Phase 3 study in Lesion in Body RegionNCT06010173 · 240 enrolled · Japan
- Sep 11, 2023Phase 3 study in Brain NeoplasmsNCT06057168 · 138 enrolled · Hungary, Italy, Poland
- Jan 15, 2026Phase 3 study in Steno-occlusive DiseaseNCT07348640 · 315 planned · United States, Canada, Czechia and more
Ahead
- Dec 31, 2027Primary completion: phase 3 study in Steno-occlusive DiseaseNCT07348640
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 12 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07348640Steno-occlusive Disease · United States, Canada, Czechia and more | 3 | Recruiting | Dec 31, 2027 | 315 |
| NCT06057168Brain Neoplasms · Hungary, Italy, Poland | 3 | Completed | Nov 28, 2024 | 138 |
| NCT06010173Lesion in Body Region · Japan | 3 | Completed | May 6, 2025 | 240 |
| NCT05590884Central Nervous System Diseases · United States, Hungary, Poland | 2 | Completed | Sep 30, 2024 | 36 |
| NCT04906005Pharmacokinetics · Japan | 1 | Completed | Jul 27, 2021 | 27 |
| NCT03996447CNS Lesion · United States, Belgium, France and more | 3 | Completed | Sep 11, 2020 | 260 |
| NCT03986138Lesion in Body Region · United States, Bulgaria, France and more | 3 | Completed | Dec 9, 2020 | 324 |
| NCT03749252Central Nervous System Indication · Bulgaria, Hungary, Poland and more | 2 | Completed | Dec 18, 2019 | 80 |
| NCT03657784Renal Insufficiency · Moldova, Republic of, Romania | 1 | Completed | Feb 1, 2019 | 40 |
| NCT03657264Healthy Volunteers · Belgium | 1 | Completed | Jun 7, 2018 | 48 |
| NCT03603106Healthy Volunteers · Belgium | 2 | Completed | Apr 17, 2015 | 142 |
| NCT02633501CNS Lesion · United States, Belgium, Czechia and more | 2 | Completed | Jan 2018 | 312 |
How it is read
Names in the registry
- “gadopiclenol”, 4 entries
- “P03277”, 4 entries
- “Gadopiclenol”, 2 entries
- “Elucirem”, 1 entry
- “P03277 0.1 mmol/kg”, 1 entry
Conditions, from the studies’ own filings
- Brain Neoplasms, 1 study
- Central Nervous System Diseases, 1 study
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.